Israeli company Kamada, which develops treatments for orphan diseases, has raised less than it aimed for on its Nasdaq IPO. The company was hoping to raise up to $69 million, but was only able to raise $51.6 million.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Clean Energy Firm Completes Solar Project In North, South Israel
October 15, 2024
Cannabis Therapy Firm: CBD Jab Reduces Pain In Arthritic Dogs
October 15, 2024
US Government Funding Development Of Israeli Ebola Treatment
October 14, 2024
Security Firm Wins Prison Service Contract For Electronic Monitoring
October 14, 2024
Facebook comments